Verici Dx plc
("Verici Dx" or the "Company")
Transfer of urine samples to Thermo Fisher Scientific
Following completion of the transfer, full payment has been received
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has completed successful transfer of a portion of the Company's urine samples as announced as part of the global commercialisation and licensing agreement announced in November 20231. As previously stated, it demonstrates the additional value in the Company's data and sample assets for research.
Sara Barrington, CEO, said:
"We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in the Company's data and sample assets for research purposes."
Enquiries:
| Verici Dx | |
| Sara Barrington, CEO | investors@vericidx.com |
| Julian Baines, Chairman |
|
| | |
|
|
|
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 20 7496 3000 |
| Aubrey Powell / Sam Butcher | |
| | |
Notes
1. Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/44270
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.